Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 255

1.

Wnt/PCP Signaling Contribution to Carcinoma Collective Cell Migration and Metastasis.

VanderVorst K, Dreyer CA, Konopelski SE, Lee H, Ho HH, Carraway KL 3rd.

Cancer Res. 2019 Apr 15;79(8):1719-1729. doi: 10.1158/0008-5472.CAN-18-2757. Epub 2019 Apr 5. Review.

PMID:
30952630
2.

Otubain 1: a non-canonical deubiquitinase with an emerging role in cancer.

Saldana M, VanderVorst K, Berg AL, Lee H, Carraway KL.

Endocr Relat Cancer. 2019 Jan 1;26(1):R1-R14. doi: 10.1530/ERC-18-0264. Review.

PMID:
30400005
3.

Single-Molecule Fluorescence Detection of the Epidermal Growth Factor Receptor in Membrane Discs.

Quinn SD, Srinivasan S, Gordon JB, He W, Carraway KL 3rd, Coleman MA, Schlau-Cohen GS.

Biochemistry. 2019 Jan 29;58(4):286-294. doi: 10.1021/acs.biochem.8b00089. Epub 2018 Apr 6.

PMID:
29553754
4.

Cellular and molecular mechanisms underlying planar cell polarity pathway contributions to cancer malignancy.

VanderVorst K, Hatakeyama J, Berg A, Lee H, Carraway KL 3rd.

Semin Cell Dev Biol. 2018 Sep;81:78-87. doi: 10.1016/j.semcdb.2017.09.026. Epub 2017 Nov 4. Review.

PMID:
29107170
5.

Membrane Mucin Muc4 promotes blood cell association with tumor cells and mediates efficient metastasis in a mouse model of breast cancer.

Rowson-Hodel AR, Wald JH, Hatakeyama J, O'Neal WK, Stonebraker JR, VanderVorst K, Saldana MJ, Borowsky AD, Sweeney C, Carraway KL 3rd.

Oncogene. 2018 Jan 11;37(2):197-207. doi: 10.1038/onc.2017.327. Epub 2017 Sep 11.

6.

Replication Study: The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.

Showalter MR, Hatakeyama J, Cajka T, VanderVorst K, Carraway KL, Fiehn O; Reproducibility Project: Cancer Biology.

Elife. 2017 Jun 27;6. pii: e26030. doi: 10.7554/eLife.26030.

7.

Synthesis and biochemical characterization of EGF receptor in a water-soluble membrane model system.

Scharadin TM, He W, Yiannakou Y, Tomilov AA, Saldana M, Cortopassi GA, Carraway KL 3rd, Coleman MA, Henderson PT.

PLoS One. 2017 Jun 6;12(6):e0177761. doi: 10.1371/journal.pone.0177761. eCollection 2017.

8.

Membrane Protein Quantity Control at the Endoplasmic Reticulum.

Printsev I, Curiel D, Carraway KL 3rd.

J Membr Biol. 2017 Aug;250(4):379-392. doi: 10.1007/s00232-016-9931-0. Epub 2016 Oct 14. Review.

9.

The ER structural protein Rtn4A stabilizes and enhances signaling through the receptor tyrosine kinase ErbB3.

Hatakeyama J, Wald JH, Rafidi H, Cuevas A, Sweeney C, Carraway KL 3rd.

Sci Signal. 2016 Jun 28;9(434):ra65. doi: 10.1126/scisignal.aaf1604.

10.

Regulation of the T-box transcription factor Tbx3 by the tumour suppressor microRNA-206 in breast cancer.

Amir S, Simion C, Umeh-Garcia M, Krig S, Moss T, Carraway KL 3rd, Sweeney C.

Br J Cancer. 2016 May 10;114(10):1125-34. doi: 10.1038/bjc.2016.73. Epub 2016 Apr 21.

11.

Hexamethylene amiloride engages a novel reactive oxygen species- and lysosome-dependent programmed necrotic mechanism to selectively target breast cancer cells.

Rowson-Hodel AR, Berg AL, Wald JH, Hatakeyama J, VanderVorst K, Curiel DA, Leon LJ, Sweeney C, Carraway KL 3rd.

Cancer Lett. 2016 May 28;375(1):62-72. doi: 10.1016/j.canlet.2016.02.042. Epub 2016 Mar 2.

12.

Cell-free expression of functional receptor tyrosine kinases.

He W, Scharadin TM, Saldana M, Gellner C, Hoang-Phou S, Takanishi C, Hura GL, Tainer JA, Carraway KL 3rd, Henderson PT, Coleman MA.

Sci Rep. 2015 Aug 14;5:12896. doi: 10.1038/srep12896.

13.

Transcription of Nrdp1 by the androgen receptor is regulated by nuclear filamin A in prostate cancer.

Savoy RM, Chen L, Siddiqui S, Melgoza FU, Durbin-Johnson B, Drake C, Jathal MK, Bose S, Steele TM, Mooso BA, D'Abronzo LS, Fry WH, Carraway KL 3rd, Mudryj M, Ghosh PM.

Endocr Relat Cancer. 2015 Jun;22(3):369-86. doi: 10.1530/ERC-15-0021. Epub 2015 Mar 10.

14.

Vangl1 and Vangl2: planar cell polarity components with a developing role in cancer.

Hatakeyama J, Wald JH, Printsev I, Ho HY, Carraway KL 3rd.

Endocr Relat Cancer. 2014 Oct;21(5):R345-56. doi: 10.1530/ERC-14-0141. Epub 2014 Jun 30. Review.

15.

Novel sorafenib-based structural analogues: in-vitro anticancer evaluation of t-MTUCB and t-AUCMB.

Wecksler AT, Hwang SH, Wettersten HI, Gilda JE, Patton A, Leon LJ, Carraway KL 3rd, Gomes AV, Baar K, Weiss RH, Hammock BD.

Anticancer Drugs. 2014 Apr;25(4):433-46. doi: 10.1097/CAD.0000000000000079.

16.

Oligomerization of the Nrdp1 E3 ubiquitin ligase is necessary for efficient autoubiquitination but not ErbB3 ubiquitination.

Printsev I, Yen L, Sweeney C, Carraway KL 3rd.

J Biol Chem. 2014 Mar 21;289(12):8570-8. doi: 10.1074/jbc.M113.527036. Epub 2014 Feb 11.

17.

CTEN prolongs signaling by EGFR through reducing its ligand-induced degradation.

Hong SY, Shih YP, Li T, Carraway KL 3rd, Lo SH.

Cancer Res. 2013 Aug 15;73(16):5266-76. doi: 10.1158/0008-5472.CAN-12-4441. Epub 2013 Jun 17.

18.

Leucine-rich repeat and immunoglobulin domain-containing protein-1 (Lrig1) negative regulatory action toward ErbB receptor tyrosine kinases is opposed by leucine-rich repeat and immunoglobulin domain-containing protein 3 (Lrig3).

Rafidi H, Mercado F 3rd, Astudillo M, Fry WH, Saldana M, Carraway KL 3rd, Sweeney C.

J Biol Chem. 2013 Jul 26;288(30):21593-605. doi: 10.1074/jbc.M113.486050. Epub 2013 May 30.

19.

A cell-permeant amiloride derivative induces caspase-independent, AIF-mediated programmed necrotic death of breast cancer cells.

Leon LJ, Pasupuleti N, Gorin F, Carraway KL 3rd.

PLoS One. 2013 Apr 30;8(4):e63038. doi: 10.1371/journal.pone.0063038. Print 2013.

20.

CD44 interacts with EGFR and promotes head and neck squamous cell carcinoma initiation and progression.

Perez A, Neskey DM, Wen J, Pereira L, Reategui EP, Goodwin WJ, Carraway KL, Franzmann EJ.

Oral Oncol. 2013 Apr;49(4):306-13. doi: 10.1016/j.oraloncology.2012.11.009. Epub 2012 Dec 20.

21.

5-Benzylglycinyl-amiloride kills proliferating and nonproliferating malignant glioma cells through caspase-independent necroptosis mediated by apoptosis-inducing factor.

Pasupuleti N, Leon L, Carraway KL 3rd, Gorin F.

J Pharmacol Exp Ther. 2013 Mar;344(3):600-15. doi: 10.1124/jpet.112.200519. Epub 2012 Dec 14.

22.

Galectin-3 regulates intracellular trafficking of EGFR through Alix and promotes keratinocyte migration.

Liu W, Hsu DK, Chen HY, Yang RY, Carraway KL 3rd, Isseroff RR, Liu FT.

J Invest Dermatol. 2012 Dec;132(12):2828-37. doi: 10.1038/jid.2012.211. Epub 2012 Jul 12.

23.

Lrig1 is an estrogen-regulated growth suppressor and correlates with longer relapse-free survival in ERα-positive breast cancer.

Krig SR, Frietze S, Simion C, Miller JK, Fry WH, Rafidi H, Kotelawala L, Qi L, Griffith OL, Gray JW, Carraway KL 3rd, Sweeney C.

Mol Cancer Res. 2011 Oct;9(10):1406-17. doi: 10.1158/1541-7786.MCR-11-0227. Epub 2011 Aug 5.

24.

MUC1 and MUC4: switching the emphasis from large to small.

Albrecht H, Carraway KL 3rd.

Cancer Biother Radiopharm. 2011 Jun;26(3):261-71. doi: 10.1089/cbr.2011.1017. Review.

25.

Quantity control of the ErbB3 receptor tyrosine kinase at the endoplasmic reticulum.

Fry WH, Simion C, Sweeney C, Carraway KL 3rd.

Mol Cell Biol. 2011 Jul;31(14):3009-18. doi: 10.1128/MCB.05105-11. Epub 2011 May 16.

26.

Dual inhibition of sodium-mediated proton and calcium efflux triggers non-apoptotic cell death in malignant gliomas.

Harley W, Floyd C, Dunn T, Zhang XD, Chen TY, Hegde M, Palandoken H, Nantz MH, Leon L, Carraway KL 3rd, Lyeth B, Gorin FA.

Brain Res. 2010 Dec 2;1363:159-69. doi: 10.1016/j.brainres.2010.09.059. Epub 2010 Oct 13.

27.

E3 ubiquitin ligases in ErbB receptor quantity control.

Carraway KL 3rd.

Semin Cell Dev Biol. 2010 Dec;21(9):936-43. doi: 10.1016/j.semcdb.2010.09.006. Epub 2010 Sep 22. Review.

28.

Post-transcriptional mechanisms contribute to the suppression of the ErbB3 negative regulator protein Nrdp1 in mammary tumors.

Ingalla EQ, Miller JK, Wald JH, Workman HC, Kaur RP, Yen L, Fry WH, Borowsky AD, Young LJ, Sweeney C, Carraway KL 3rd.

J Biol Chem. 2010 Sep 10;285(37):28691-7. doi: 10.1074/jbc.M110.127977. Epub 2010 Jul 13.

29.

Nrdp1-mediated regulation of ErbB3 expression by the androgen receptor in androgen-dependent but not castrate-resistant prostate cancer cells.

Chen L, Siddiqui S, Bose S, Mooso B, Asuncion A, Bedolla RG, Vinall R, Tepper CG, Gandour-Edwards R, Shi X, Lu XH, Siddiqui J, Chinnaiyan AM, Mehra R, Devere White RW, Carraway KL 3rd, Ghosh PM.

Cancer Res. 2010 Jul 15;70(14):5994-6003. doi: 10.1158/0008-5472.CAN-09-4440. Epub 2010 Jun 29.

30.

Mechanistic and signaling analysis of Muc4-ErbB2 signaling module: new insights into the mechanism of ligand-independent ErbB2 activity.

Kozloski GA, Carraway CA, Carraway KL.

J Cell Physiol. 2010 Sep;224(3):649-57. doi: 10.1002/jcp.22163.

31.
32.

Diacylglycerol kinase delta and protein kinase C(alpha) modulate epidermal growth factor receptor abundance and degradation through ubiquitin-specific protease 8.

Cai J, Crotty TM, Reichert E, Carraway KL 3rd, Stafforini DM, Topham MK.

J Biol Chem. 2010 Mar 5;285(10):6952-9. doi: 10.1074/jbc.M109.055731. Epub 2010 Jan 11.

33.

Regulation of the membrane mucin Muc4 in corneal epithelial cells by proteosomal degradation and TGF-beta.

Lomako J, Lomako WM, Carothers Carraway CA, Carraway KL.

J Cell Physiol. 2010 Apr;223(1):209-14. doi: 10.1002/jcp.22028.

34.

Muc4/MUC4 functions and regulation in cancer.

Carraway KL, Theodoropoulos G, Kozloski GA, Carothers Carraway CA.

Future Oncol. 2009 Dec;5(10):1631-40. doi: 10.2217/fon.09.125. Review.

35.

The membrane mucin MUC4 is elevated in breast tumor lymph node metastases relative to matched primary tumors and confers aggressive properties to breast cancer cells.

Workman HC, Miller JK, Ingalla EQ, Kaur RP, Yamamoto DI, Beckett LA, Young LJ, Cardiff RD, Borowsky AD, Carraway KL, Sweeney C, Carraway KL 3rd.

Breast Cancer Res. 2009;11(5):R70. doi: 10.1186/bcr2364.

36.

TGFbeta regulation of membrane mucin Muc4 via proteosome degradation.

Lomako WM, Lomako J, Soto P, Carraway CA, Carraway KL.

J Cell Biochem. 2009 Jul 1;107(4):797-802. doi: 10.1002/jcb.22177.

37.

The membrane mucin Muc4 inhibits apoptosis induced by multiple insults via ErbB2-dependent and ErbB2-independent mechanisms.

Workman HC, Sweeney C, Carraway KL 3rd.

Cancer Res. 2009 Apr 1;69(7):2845-52. doi: 10.1158/0008-5472.CAN-08-2089. Epub 2009 Mar 17.

38.

MUC4 involvement in ErbB2/ErbB3 phosphorylation and signaling in response to airway cell mechanical injury.

Theodoropoulos G, Carraway CA, Carraway KL.

J Cell Biochem. 2009 May 1;107(1):112-22. doi: 10.1002/jcb.22106.

PMID:
19288496
39.

Suppression of the negative regulator LRIG1 contributes to ErbB2 overexpression in breast cancer.

Miller JK, Shattuck DL, Ingalla EQ, Yen L, Borowsky AD, Young LJ, Cardiff RD, Carraway KL 3rd, Sweeney C.

Cancer Res. 2008 Oct 15;68(20):8286-94. doi: 10.1158/0008-5472.CAN-07-6316.

40.

Mechanisms of ErbB receptor negative regulation and relevance in cancer.

Fry WH, Kotelawala L, Sweeney C, Carraway KL 3rd.

Exp Cell Res. 2009 Feb 15;315(4):697-706. doi: 10.1016/j.yexcr.2008.07.022. Epub 2008 Jul 31. Review.

41.

LRIG1 negatively regulates the oncogenic EGF receptor mutant EGFRvIII.

Stutz MA, Shattuck DL, Laederich MB, Carraway KL 3rd, Sweeney C.

Oncogene. 2008 Sep 25;27(43):5741-52. doi: 10.1038/onc.2008.185. Epub 2008 Jun 9.

42.

Combined defects in epithelial and immunoregulatory factors exacerbate the pathogenesis of inflammation: mucin 2-interleukin 10-deficient mice.

van der Sluis M, Bouma J, Vincent A, Velcich A, Carraway KL, Büller HA, Einerhand AW, van Goudoever JB, Van Seuningen I, Renes IB.

Lab Invest. 2008 Jun;88(6):634-42. doi: 10.1038/labinvest.2008.28. Epub 2008 Apr 21.

43.

MUC4 interacts with ErbB2 in human gallbladder carcinoma: potential pathobiological implications.

Miyahara N, Shoda J, Ishige K, Kawamoto T, Ueda T, Taki R, Ohkohchi N, Hyodo I, Thomas MB, Krishnamurthy S, Carraway KL, Irimura T.

Eur J Cancer. 2008 May;44(7):1048-56. doi: 10.1016/j.ejca.2008.03.007. Epub 2008 Apr 7.

PMID:
18397823
44.

Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells.

Shattuck DL, Miller JK, Carraway KL 3rd, Sweeney C.

Cancer Res. 2008 Mar 1;68(5):1471-7. doi: 10.1158/0008-5472.CAN-07-5962.

45.

Molecular signaling in the regulation of mucins.

Theodoropoulos G, Carraway KL.

J Cell Biochem. 2007 Dec 1;102(5):1103-16. Review.

PMID:
17957706
46.

Soluble CD44 is a potential marker for the early detection of head and neck cancer.

Franzmann EJ, Reategui EP, Pedroso F, Pernas FG, Karakullukcu BM, Carraway KL, Hamilton K, Singal R, Goodwin WJ.

Cancer Epidemiol Biomarkers Prev. 2007 Jul;16(7):1348-55.

47.

The human mucin MUC4 is transcriptionally regulated by caudal-related homeobox, hepatocyte nuclear factors, forkhead box A, and GATA endodermal transcription factors in epithelial cancer cells.

Jonckheere N, Vincent A, Perrais M, Ducourouble MP, Male AK, Aubert JP, Pigny P, Carraway KL, Freund JN, Renes IB, Van Seuningen I.

J Biol Chem. 2007 Aug 3;282(31):22638-50. Epub 2007 Jun 6.

48.

Sequestration and segregation of receptor kinases in epithelial cells: implications for ErbB2 oncogenesis.

Carraway CA, Carraway KL.

Sci STKE. 2007 Apr 10;2007(381):re3. Review.

PMID:
17426346
49.

Contribution of membrane mucins to tumor progression through modulation of cellular growth signaling pathways.

Carraway KL 3rd, Funes M, Workman HC, Sweeney C.

Curr Top Dev Biol. 2007;78:1-22. Review.

PMID:
17338913
50.

Neuregulin-induced ErbB3 downregulation is mediated by a protein stability cascade involving the E3 ubiquitin ligase Nrdp1.

Cao Z, Wu X, Yen L, Sweeney C, Carraway KL 3rd.

Mol Cell Biol. 2007 Mar;27(6):2180-8. Epub 2007 Jan 8.

Supplemental Content

Loading ...
Support Center